Novo Nordisk: Mr. Market Is Pricing In Success, But It's Too Early To Bank On That

Novo Nordisk remains a ‘hold’ as persistent drug weakness offsets strong valuation and recent outperformance. NVO’s adjusted revenue declined 10.3% YoY, driven by Ozempic and Rybelsus weakness, despite profitability and cash flow improvements. Pipeline progress in obesity and diabetes, including CagriSema and Zenagamtide, offers potential but lacks near-term catalysts. Valuation appears cheap versus peers, but justified by market share loss and analyst expectations for further revenue and profit declines.

Over the last few months, shares of Novo Nordisk A/S ( NVO ) have done exceptionally well. Even though revenue for the company, on an adjusted basis, has been declining, profitability and cash flows have been on the rise. This, combined with the